Gene · 4102
Papers3,353
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
761 to 780 of 3,353
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Set Up for Failure: Pre-Existing Autoantibodies in Lung Transplant. | Front Immunol | 2021 | 34456920 | PubTator, text mining | PubMed |
| The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines). | Curr Oncol Rep | 2021 | 34453261 | PubTator, text mining | PubMed |
| DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. | Clin Epigenetics | 2021 | 34452630 | PubTator, text mining | PubMed |
| Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies. | Viruses | 2021 | 34452286 | PubTator, text mining | PubMed |
| Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications. | Front Immunol | 2021 | 34447376 | PubTator, text mining | PubMed |
| Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. | J Immunother Cancer | 2021 | 34446575 | PubTator, text mining | PubMed |
| CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy. | J Exp Clin Cancer Res | 2021 | 34446084 | PubTator, text mining | PubMed |
| Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997-2020). | Healthcare (Basel) | 2021 | 34442199 | PubTator, text mining | PubMed |
| Unraveling the Wide Spectrum of Melanoma Biomarkers. | Diagnostics (Basel) | 2021 | 34441278 | PubTator, text mining | PubMed |
| Understanding Cervical Cancer through Proteomics. | Cells | 2021 | 34440623 | PubTator, text mining | PubMed |
| Exosomal Components and Modulators in Colorectal Cancer: Novel Diagnosis and Prognosis Biomarkers. | Biomedicines | 2021 | 34440135 | PubTator, text mining | PubMed |
| Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future. | Cancers (Basel) | 2021 | 34439273 | PubTator, text mining | PubMed |
| EVI2B Is a New Prognostic Biomarker in Metastatic Melanoma with IFNgamma Associated Immune Infiltration. | Cancers (Basel) | 2021 | 34439264 | PubTator, text mining | PubMed |
| PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches. | Cancers (Basel) | 2021 | 34439194 | PubTator, text mining | PubMed |
| Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers. | J Immunother | 2021 | 34432728 | PubTator, text mining | PubMed |
| Interpretable systems biomarkers predict response to immune-checkpoint inhibitors. | Patterns (N Y) | 2021 | 34430923 | PubTator, text mining | PubMed |
| Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies. | Transl Lung Cancer Res | 2021 | 34430349 | PubTator, text mining | PubMed |
| Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review. | Front Oncol | 2021 | 34422659 | PubTator, text mining | PubMed |
| A high-affinity human TCR-like antibody detects celiac disease gluten peptide-MHC complexes and inhibits T cell activation. | Sci Immunol | 2021 | 34417258 | PubTator, text mining | PubMed |
| Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma. | J Immunother Cancer | 2021 | 34413169 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4102/papers?page=39